“It is important to our organization to use every avenue possible as we work to provide our patients with medications that are needed for daily life, so to have sanofi-aventis U.S. join us as we strive to seek and dispense medications speaks highly of the company’s commitment to help patients in need obtain quality prescription medication,” said Scott Cornwell, chief operating officer of Dispensary for Hope.

“Throughout his career, Dr. Riley has been a leader in public health administration and patient care and will provide a unique perspective to our board as we seek to bring breakthrough medicines to people with serious diseases," said Matthew Emmens, Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals. “In addition, Dr. Riley’s clinical and operational experience in the public health systems of major urban centers and at large academic medical institutions will be invaluable in our efforts to address the needs of people with hepatitis C and those involved with treatment of this disease.”

“The 52 week data from the Augment North American pivotal clinical trial demonstrate that patients treated with Augment have just as good an outcome after one year, and a favorable safety profile, compared to patients treated with autograft," said BioMimetic CEO Sam Lynch in a statement. "And, the patients treated with Augment have the added benefits of not having the additional pain and risk of a procedure to harvest the autograft from another bone in their body."

“Both sides had good reasons to resolve this situation quickly,” said Adam Fein, president of Philadelphia-based Pembroke Consulting Inc., a health-care distribution consulting firm. “CVS Caremark needed to minimize damage to its PBM business, while Walgreen faced an enormous revenue hit from the loss of Caremark. Everyone also recognized the enormous disruption for patients caused by a permanent split.”